PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-80
SponsorNeuroAEye LLC

About this trial

This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss.

The primary objective is to demonstrate that there is an improvement in the visual field after use of the PAVE therapy over a period of eight weeks with three sessions per week. The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry.

The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better after PAVE therapy when compared to before therapy.

The participants will visit the investigators office at the start of the study to establish a baseline for visual field size and visual field function. The subject will use PAVE in the office or at home three times per week for eight weeks. There will be twenty four therapy sessions in total. At four weeks the subject will visit the office and have perimetry measurements. At eight weeks the subject will visit the office and have perimetry measurements and complete the NEI-VFQ survey. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.

Eligibility criteria

Qualifiers

This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset

The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.

Disqualifiers

Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.

Concurrent use of another visual therapy

Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)

Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects

Trial design

Treatments tested in this trial

  • PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators